Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 14, 2025
Daily News
October 14, 2025
- MHLW to Clarify Criteria for Japanese PI Waivers through Q&A, Calls for Data-Based Justifications
October 14, 2025
- Chugai to Develop Roche’s GLP-1/GIP Agent CT-388 in Japan
October 14, 2025
- JT, Torii File Tapinarof Cream for Pediatric Atopic Dermatitis in Japan
October 14, 2025
- Japan’s Healthcare Spending Reaches 48.1 Trillion Yen in FY2023
October 14, 2025
- PMDA Lays Out AI Action Plan, Eyes Specialized In-House System
October 14, 2025
- MHLW Panel OKs 19th Edition of Japanese Pharmacopoeia; 27 New Products Added
October 14, 2025
- MHLW Maps Out Action Plan to Tackle Drug Supply Disruptions
October 14, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…